MX2015005637A - Tratamiento o prevención de eventos cardiovasculares mediante la administración de un derivado de colchicina. - Google Patents

Tratamiento o prevención de eventos cardiovasculares mediante la administración de un derivado de colchicina.

Info

Publication number
MX2015005637A
MX2015005637A MX2015005637A MX2015005637A MX2015005637A MX 2015005637 A MX2015005637 A MX 2015005637A MX 2015005637 A MX2015005637 A MX 2015005637A MX 2015005637 A MX2015005637 A MX 2015005637A MX 2015005637 A MX2015005637 A MX 2015005637A
Authority
MX
Mexico
Prior art keywords
alkyl
prevention
treatment
optionally substituted
formula
Prior art date
Application number
MX2015005637A
Other languages
English (en)
Inventor
Mark Nidorf
Original Assignee
Murray And Poole Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50626218&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015005637(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2012904828A external-priority patent/AU2012904828A0/en
Application filed by Murray And Poole Entpr Ltd filed Critical Murray And Poole Entpr Ltd
Publication of MX2015005637A publication Critical patent/MX2015005637A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)

Abstract

Un método de tratamiento o prevención de un evento cardiovascular en un sujeto con enfermedad vascular ateroesclerótica que comprende los pasos de: b) administrar una cantidad terapéuticamente efectiva de un compuesto de la fórmula (I), un derivado de colchicina conocido y/o una sal del mismo (ver Fórmula) en la cual: R1, R2, R3, R4, R9, R10, R11 y R12 representan independientemente hidrógeno, C1-4 alquilo, C2-4 alquenilo, C3-6 cicloalquilo, halógeno, C1-4 haloalquilo, nitro, amino, C2-4 acilamino, C1-4 alquilo o dialquilamino, hidroxilo, C1-4 alcoxi, C1-4 alquiltio, un grupo de la fórmula - SO2N(Rx)2 o SO2RX donde Rx es C1-4 alquilo, C1-4 aciloxi, o fenilo opcionalmente sustituido, fenoxi opcionalmente sustituido; R7 y R8 representan independientemente hidrógeno, C1-4 alquilo o C1-4 acilo; y R5', R5'', R6' y R6'' representan independientemente hidrógeno, C1-4 alquilo, C2-4 alquenilo, C3-6 cicloalquilo, halógeno, C1-4 haloalquilo, nitro, amino, C2-4 acilamino, hidroxilo, C1-4 alcoxi o C1-4 alquiltio un grupo de la fórmula -SO2N(Rx)2 o SO2RX donde Rx es C1-4 alquilo, C1-4 aciloxi, o fenilo opcionalmente sustituido.
MX2015005637A 2012-11-02 2013-11-01 Tratamiento o prevención de eventos cardiovasculares mediante la administración de un derivado de colchicina. MX2015005637A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012904828A AU2012904828A0 (en) 2012-11-02 Treatment and Prevention of Coronary Thrombosis
AU2012904868A AU2012904868A0 (en) 2012-11-05 Treatment or Prevention of Cardiovascular Events
PCT/AU2013/001261 WO2014066944A1 (en) 2012-11-02 2013-11-01 Treatment or prevention of cardiovascular events via the administration of a colchicine derivative

Publications (1)

Publication Number Publication Date
MX2015005637A true MX2015005637A (es) 2016-02-03

Family

ID=50626218

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015005637A MX2015005637A (es) 2012-11-02 2013-11-01 Tratamiento o prevención de eventos cardiovasculares mediante la administración de un derivado de colchicina.
MX2020009511A MX2020009511A (es) 2012-11-02 2013-11-01 Tratamiento o prevención de eventos cardiovasculares.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020009511A MX2020009511A (es) 2012-11-02 2013-11-01 Tratamiento o prevención de eventos cardiovasculares.

Country Status (24)

Country Link
US (15) US10265281B2 (es)
EP (2) EP3964205A1 (es)
JP (1) JP6356684B2 (es)
KR (5) KR20210020170A (es)
CN (2) CN108721265B (es)
AU (5) AU2013337605B2 (es)
BR (1) BR112015010063B1 (es)
CA (1) CA2894417C (es)
CL (1) CL2015001154A1 (es)
DK (1) DK2914255T3 (es)
EA (1) EA032515B1 (es)
ES (1) ES2900740T3 (es)
HR (1) HRP20211644T1 (es)
HU (1) HUE056810T2 (es)
IL (1) IL238519B (es)
LT (1) LT2914255T (es)
MX (2) MX2015005637A (es)
MY (1) MY177898A (es)
NZ (2) NZ707640A (es)
PL (1) PL2914255T3 (es)
PT (1) PT2914255T (es)
SG (2) SG11201503440UA (es)
SI (1) SI2914255T1 (es)
WO (1) WO2014066944A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013337605B2 (en) 2012-11-02 2018-03-01 Murray & Poole Enterprises, Ltd. Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
PL2986280T3 (pl) 2013-04-16 2021-10-25 Murray & Poole Enterprises, Ltd. Preparat kolchicyny w postaci o przedłużonym uwalnianiu i metody tworzenia takiego samego
WO2016166732A1 (en) * 2015-04-17 2016-10-20 Murray And Poole Enterprises Limited Colchicine salicylate and uses thereof
US9907751B2 (en) 2016-03-10 2018-03-06 RxOMEG Therapeutics LLC Composition and method of use of colchicine oral liquid
US10226423B1 (en) 2017-12-20 2019-03-12 RxOMEG Therapeutics LLC Colchicine drug-to-drug interactions
JP2022514997A (ja) 2018-02-02 2022-02-17 マリー アンド プール エンタープライゼズ，リミテッド 腫瘍の増殖及び転移を阻害するためのコルヒチンの使用
KR102112456B1 (ko) 2019-11-13 2020-05-19 주식회사 에이스바이오메드 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제
US11400063B2 (en) 2019-11-15 2022-08-02 Institut De Cardiologie De Montreal Early administration of low-dose colchicine after myocardial infarction
EP3821889A1 (en) * 2019-11-15 2021-05-19 Institut de Cardiologie de Montréal Methods for using low-dose colchicine after myocarial infarction
KR102150821B1 (ko) 2020-01-22 2020-09-03 주식회사 에이스바이오메드 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제
KR20210095249A (ko) 2020-01-22 2021-08-02 주식회사 에이스바이오메드 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제
KR102177781B1 (ko) 2020-04-27 2020-11-12 주식회사 에이스바이오메드 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친, 우르소데옥시콜산 및 비페닐디메틸디카르복실레이트의 복합제제
EP4262771A1 (en) * 2020-12-15 2023-10-25 Romeg Therapeutics LLC Methods and compositions for treating pericarditis
WO2022212655A1 (en) * 2021-03-31 2022-10-06 Amarin Pharmaceuticals Ireland Limited Compositions comprising epa and colchicine and methods of using the same for reducing the risk of cardiovascular events in a subject
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
CN114656429A (zh) * 2021-11-18 2022-06-24 江苏新元素医药科技有限公司 一类抗炎镇痛化合物及其用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
US7820383B2 (en) 1997-03-10 2010-10-26 Interleukin Genetics, Inc. Method for diagnosing myocardial infarction
JP2000034224A (ja) 1998-05-11 2000-02-02 Freunt Ind Co Ltd 徐放性錠剤、その添加剤組成物及びそれらの製造方法
US20020169145A1 (en) 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
NZ519466A (en) 1999-12-22 2004-02-27 Pharmacia Corp Sustained-release formulation of a cyclooxygenase-2 inhibitor
AU2002244295B2 (en) 2001-03-13 2006-02-09 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms containing glucocorticosteroid
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20030144203A1 (en) 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
ATE441012T1 (de) 2001-12-21 2009-09-15 Prospective Concepts Ag Druckstab für pneumatische bauelemente
SE0401031D0 (sv) 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
WO2006063091A2 (en) 2004-12-06 2006-06-15 Ronald Freudenberger Use of oxypurinol as an inhibitor of anti-neoplastic agent-induced cardiotoxicity
US20060171948A1 (en) * 2005-02-02 2006-08-03 Weinstein Steven P Methods of using IL-1 antagonists to reduce C-reactive protein
US20060286108A1 (en) * 2005-06-16 2006-12-21 Bell Katherine A Topical compositions for the treatment of chronic wounds
CN1939290A (zh) * 2005-09-29 2007-04-04 陆宪光 秋水仙碱及它的衍生物的医学用途
WO2007048004A2 (en) * 2005-10-21 2007-04-26 Cornell Research Foundation, Inc. Compounds for enhancing hypoxia inducible factor activity and methods of use
EP2023874A4 (en) 2006-06-02 2009-07-08 Bioseek Inc METHOD FOR IDENTIFYING ACTIVE SUBSTANCES AND THEIR USE FOR THE PREVENTION OF RESTENOSIS
CN101466371B (zh) 2006-06-09 2011-10-05 施瓦茨制药有限公司 含非索罗定的稳定的药用组合物
WO2008131192A2 (en) * 2007-04-18 2008-10-30 The Trustees Of Columbia University In The City Of New York Crystalline cholestrol and prevention of atherosclerosis
US20090093548A1 (en) 2007-10-05 2009-04-09 Mutual Pharmaceutical Company, Inc Colchine compositions and methods
CN101485637B (zh) 2008-01-18 2011-03-30 普尔药物科技开发（深圳）有限公司 秋水仙碱骨架控释片或胶囊
CN101485638A (zh) 2008-01-18 2009-07-22 普尔药物科技开发（深圳）有限公司 秋水仙碱双层渗透泵控释片及其制备方法
US20090299155A1 (en) 2008-01-30 2009-12-03 Dexcom, Inc. Continuous cardiac marker sensor system
CN101536990A (zh) 2008-03-18 2009-09-23 普尔药物科技开发（深圳）有限公司 秋水仙碱胃漂浮缓释片及其制备方法
US8309764B2 (en) 2008-04-15 2012-11-13 Mutual Pharmaceutical Company, Inc. Colchicine solid-state forms; methods of making; and methods of use thereof
PT2128170E (pt) 2008-05-28 2011-02-23 Indena Spa Processo para a glicosidação de colchicina e tiocolchicina
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
GB0819287D0 (en) * 2008-10-22 2008-11-26 Univ Bradford Compounds
CN101732274A (zh) 2008-11-19 2010-06-16 普尔药物科技开发（深圳）有限公司 秋水仙碱双层缓释片及其制备方法
US7820681B1 (en) * 2009-01-14 2010-10-26 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
US8945622B2 (en) 2009-03-09 2015-02-03 Council Of Scientific And Industrial Research Sustained release composition of therapeutic agent
EP2435403A4 (en) 2009-05-27 2015-04-01 Takeda Pharmaceuticals Usa Inc THIOCOLCHICINE DERIVATIVES AND MANUFACTURING AND USE METHOD THEREFOR
US20110046228A1 (en) 2009-08-20 2011-02-24 Mutual Pharmaceutical Company, Inc. Methods for administration of colchicine with grapefruit juice
US20110046227A1 (en) * 2009-08-21 2011-02-24 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
ES2745255T3 (es) 2009-08-26 2020-02-28 Alberta Health Services Derivados de colchicina novedosos, métodos y usos de los mismos
ES2689107T3 (es) 2009-11-13 2018-11-08 Astrazeneca Ab Formulaciones de tabletas bicapa
US20110178180A1 (en) 2010-01-18 2011-07-21 Kurt Nielsen Deuterium-enriched colchicine, thiocolchicine, and derivatives thereof; methods of preparation; and use thereof
EP2481411A1 (en) 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
SG11201406495UA (en) 2012-04-13 2014-11-27 Cymabay Therapeutics Inc Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
AU2013337605B2 (en) 2012-11-02 2018-03-01 Murray & Poole Enterprises, Ltd. Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
PL2986280T3 (pl) 2013-04-16 2021-10-25 Murray & Poole Enterprises, Ltd. Preparat kolchicyny w postaci o przedłużonym uwalnianiu i metody tworzenia takiego samego

Also Published As

Publication number Publication date
MY177898A (en) 2020-09-24
US20210069131A1 (en) 2021-03-11
EP2914255B1 (en) 2021-07-21
US20150196513A1 (en) 2015-07-16
US10842761B2 (en) 2020-11-24
KR20220001518A (ko) 2022-01-05
EP3964205A1 (en) 2022-03-09
CN104918613B (zh) 2018-05-25
EA201500484A1 (ru) 2015-10-30
NZ707640A (en) 2019-03-29
US20240082179A1 (en) 2024-03-14
KR20150102969A (ko) 2015-09-09
US20150196514A1 (en) 2015-07-16
US20150272912A1 (en) 2015-10-01
KR20240074883A (ko) 2024-05-28
CA2894417C (en) 2019-09-10
SG10201703586PA (en) 2017-06-29
US11026900B2 (en) 2021-06-08
US11026899B2 (en) 2021-06-08
US9744144B2 (en) 2017-08-29
DK2914255T3 (da) 2021-10-25
CN108721265A (zh) 2018-11-02
CN108721265B (zh) 2022-12-02
HUE056810T2 (hu) 2022-03-28
US20190117598A1 (en) 2019-04-25
BR112015010063A2 (pt) 2018-12-18
NZ747657A (en) 2019-12-20
EA032515B1 (ru) 2019-06-28
PL2914255T3 (pl) 2022-01-03
HRP20211644T1 (hr) 2022-02-04
LT2914255T (lt) 2021-11-10
AU2018203715B2 (en) 2019-06-20
US20190314303A1 (en) 2019-10-17
EP2914255A4 (en) 2016-06-29
AU2018203715A1 (en) 2018-06-21
CN104918613A (zh) 2015-09-16
AU2013337605B2 (en) 2018-03-01
US11944595B2 (en) 2024-04-02
KR20210020170A (ko) 2021-02-23
CA2894417A1 (en) 2014-05-08
MX2020009511A (es) 2022-05-09
AU2021282491A1 (en) 2022-01-06
US20230270698A1 (en) 2023-08-31
AU2024205084A1 (en) 2024-08-15
US20210069133A1 (en) 2021-03-11
US11666545B2 (en) 2023-06-06
US10206891B2 (en) 2019-02-19
WO2014066944A1 (en) 2014-05-08
PT2914255T (pt) 2021-10-27
AU2019232879A1 (en) 2019-10-10
CL2015001154A1 (es) 2015-12-18
AU2021282491B2 (en) 2024-05-09
US20210077432A1 (en) 2021-03-18
US20210069132A1 (en) 2021-03-11
IL238519A0 (en) 2015-06-30
JP2015535264A (ja) 2015-12-10
AU2019232879B2 (en) 2021-09-09
US10842762B2 (en) 2020-11-24
SI2914255T1 (sl) 2021-12-31
US20230414539A1 (en) 2023-12-28
US20230270697A1 (en) 2023-08-31
ES2900740T3 (es) 2022-03-18
BR112015010063B1 (pt) 2021-11-09
IL238519B (en) 2020-04-30
AU2013337605A1 (en) 2015-05-21
US20170326083A1 (en) 2017-11-16
US10265281B2 (en) 2019-04-23
EP2914255A1 (en) 2015-09-09
KR102666548B1 (ko) 2024-05-21
US11026901B2 (en) 2021-06-08
US11944594B2 (en) 2024-04-02
SG11201503440UA (en) 2015-06-29
KR20230049751A (ko) 2023-04-13
JP6356684B2 (ja) 2018-07-11
US20190374487A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
MX2015005637A (es) Tratamiento o prevención de eventos cardiovasculares mediante la administración de un derivado de colchicina.
MX2014001595A (es) Compuestos de imidazol, composiciones y metodos de uso.
MY177250A (en) Novel nicotinamide derivative or salt thereof
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
EA201400358A1 (ru) Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с
NZ591728A (en) Cephalosporin having catechol group
GEP20156389B (en) Oxazolidin-2-one compounds and their usage as pi3ks inhibitors
MY176488A (en) 1, 4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
UA95976C2 (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-b]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
HRP20110451T1 (hr) Upotreba izotiocijanata kao sredstva protiv mieloma
HRP20090235B1 (hr) Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d
TW200744595A (en) Quinoline derivatives as antibacterial agents
AR086242A1 (es) Procedimiento de tratar el dolor por cancer y cancer de huesos
AR087995A1 (es) Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida
ATE533489T1 (de) Behandlung von multiplem myelom
IN2014DN05869A (es)
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
NZ610705A (en) Methods of treatment using lipid compounds
MX2014006366A (es) Metodos y composiciones para reducir la grasa y los adipocitos del cuerpo.
GEP201706656B (en) 2-thiopyrimidinones
PH12015502429A1 (en) Dicarboxylic acid compound
RU2013136895A (ru) Новое бициклическое соединение или его соль
MY165634A (en) Pyrazole compounds having therapeutic effect on multiple myeloma
WO2012131656A3 (en) Compounds for use as therapeutic agents affecting p53 expression and/or activity
MY153291A (en) Quinoline derivatives as antibacterial agents

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration